t
Haleon plc announced on 12 February 2026 that PDMR Adrian Morris, General Counsel, acquired 31 ordinary shares at £3.956 each and was awarded 31 matching shares at £Nil on 10 February 2026. Also on 10 February 2026, PDMR Jonathan Workman, President, Europe, acquired 32 ordinary shares at £3.956 each and was awarded 32 matching shares at £Nil. Both transactions, totalling 62 and 64 shares respectively, occurred under the Company's Share Reward Plan on the London Stock Exchange.
| Date | 12 Feb 2026 |
| Time | 09:00:00 |
| Category | Director/PDMR dealings |
| ID | 6734S |
Haleon plc: Director/PDMR Shareholding
12 February 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
On 11 February 2026, the Company received notification of the following transactions as detailed below.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Adrian Morris |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
General Counsel - PDMR |
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Haleon plc |
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification code |
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£3.956 |
31 |
|
|
|
|
|
£Nil |
31 (Matching Shares) |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
62 |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
10 February 2026 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Jonathan Workman |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
President, Europe - PDMR |
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Haleon plc |
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification code |
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£3.956 |
32 |
|
|
|
|
|
£Nil |
32 (Matching Shares) |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
64 |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
10 February 2026 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON) |
|||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.